Background: Motivated by the reported biological activity of 9-(b-d-xylofuranosyl)adenine (xylo-A), the synthesis of its 4′-alkoxy analogues was carried out. Methods: The starting material 9-(3-deoxy-b-d-glyceropento-3-enofuranosyl)adenine (1) was prepared from adenosine. Compound 1 was converted to the 2′,5′-bis-O-(tert-butyldimethylsilyl) derivative (2) and then to the N 6 -pivaloyl derivative (3). When 3 was reacted with metachloroperbenzoic acid in the presence of a series of alcohols, the b-d-isomer of the respective 4′-alkoxy derivative was obtained exclusively in high yield. Deprotection of these products led to the isolation of the desired 4′alkoxy analogues (8a-l) of xylo-A. Results: Antiviral evaluation revealed that none of these analogues showed inhibitory activity against a wide variety of DNA and RNA viruses. Conclusions: We assume that conformational difference of the sugar moiety of 8a-l from that of xylo-A could be attributable to their inactivity.
9-(b-d-Xylofuranosyl)adenine (xylo-A) was synthesized long ago and found to be effective in prolonging the survival time of mice bearing TA3 or Ehrlich ascites tumours [1, 2] . 9-(b-d-Arabinofuranosyl)adenine (vidarabine), which was reported to have similar antitumour properties to xylo-A, is now being used clinically as an antiviral agent.
The first example for the synthesis of 4′-alkoxy nucleosides appeared in 1975. The synthesis was accomplished by way of electrophilic addition of iodine in MeOH to 1-(5-deoxy-b-d-erythro-pent-4-enofuranosyl)uracil, a 4′,5′-unsaturated uridine, followed by displacement of the resulting 5′-iodo derivative with benzoate anion [3] . Subsequently, the 4′-methoxy analogues of thymidine, 2′-deoxyadenosine and 2′-deoxuguanosine, were synthesized by oxidizing 2,5-dideoxy-b-d-glycero-pent-4enofuranosyl nucleosides with meta-chloroperbenzoic acid (m-CPBA) in MeOH. These compounds were reported to be uniformly inhibitory against HIV [4] . A recent report from our laboratory shows that 4′-methoxy-4′-thiothymidine is also inhibitory to HIV [5] .
We report here the synthesis of the 4′-alkoxy analogues of xylo-A by employing m-CPBA oxidation of 9-(3-deoxy-b-d-glycero-pento-3-enofuranosyl)adenine (1), a 3′,4′-unsaturated nucleoside.
Methods

Chemistry
Nuclear magnetic resonance (NMR) spectra were recorded either at 400 MHz (JNM-GX 400; JEOL Ltd., Tokyo, Japan) or at 500 MHz (JNM-LA 500; JEOL Ltd.). Chemical shifts were reported relative to Me 4 Si. Mass spectra (MS) were taken in FAB mode with m-nitrobenzyl alcohol as a matrix on a JNS-SX 102A (JEOL Ltd). Ultra violet (UV) spectra were measured on a JASCO Ubest-55 spectrophotometer (JASCO Corp., Tokyo, Japan). Column chromatography was carried out on silica gel (Micro Bead Silica Gel PSQ 100B; Fuji Silysia Chemical Ltd., Aichi, Japan) Thin-layer chromatography (TLC) was performed on silica gel (precoated silica gel plate F 254 ;
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Synthesis and antiviral evaluation of 4′-alkoxy analogues of 9-(b-d-xylofuranosyl)adenine 1 H NMR (CDCl 3 ) δ -0.17, 0.07, 0.12, 0.13 (12H, each as s, SiMe), 0.80 and 0.94 (18H, each as s, Si-t-Bu), 0.98 (3H, t, J vic =7. 6 Hz, 4′-OCH 2 CH 2 CH 3 ), 1.41 (9H, s, Piv), 1.62 (2H, tt, J vic =7. 6 Hz and 6. 6 Hz, 4′-OCH 2 CH 2 CH 3 ), 3.51 and 3.60 (2H, each as dt, J vic =6. 6 and J gem =8. 7 Hz, 4′-OCH 2 ), 3.90 and 3.94 (2H, each as d, J gem =11.0 Hz, H-5′), 4.19 (1H, dd, J 2′,3′ =3.4 and J 3′,3′-OH =8. 1 Hz, H-3′), 4.54 (1H, d, J 3′,3′-OH =8. 1 Hz, 3′-OH), 4.57 (1H, dd, J 1′,2′ =4.4 and J 2′,3′ =3. 4 Hz, H-2′), 6.01 (1H, d, J 1′,2′ =4. 4 Hz, H-1′), 8 
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-4-isopropoxy-b-dxylofuranosyl]-N 6 -pivaloyladenine (5d)
This compound was obtained as a foam in 80% yield: 1 H NMR (CDCl 3 ) δ -0.18, 0.01, 0.13, 0.14 (12H, each as s, SiMe), 0.80 and 0.94 (18H, each as s, Si-t-Bu), 1.20 and 1.25 (6H, each as d, J vic =6. 1 
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-4-butoxy-b-dxylofuranosyl]-N 6 -pivaloyladenine (5e)
Since this compound was contaminated with a small amount of butanol, its analytical sample was obtained after HPLC purification: 1 
Since this compound was contaminated with a small amount of isobutanol, its analytical sample was obtained after HPLC purification: 1 
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-4-neopentyloxy-bd-xylofuranosyl]-N 6 -pivaloyladenine (5h)
This compound was prepared by using 1 (100 mg, 0.178 mmol), 65% m-CPBA (71 mg, 0.267 mmol), and neopentyl alcohol (235 mg, 2.67 mmol) in CH 2 Cl 2 (1.0 ml), and obtained as a foam in 38% yield: 1 
Preparation of 9-[2,5-bis-O-(tert-butyldimethylsilyl)-4methoxy-b-d-xylofuranosyl]adenine (6a) from 5a as a typical procedure
Compound 5a (659.2 mg, 1.08 mmol) was treated with NH 3 /MeOH (60 ml) at 0°C for 28 h. Evaporation of the solvent followed by column chromatography (hexane/EtOAc=1/1) of the residue gave 6a (563.3 mg, 99%, foam): UV (MeOH): λ max 260 nm (ε 15,400), λ min 229 nm (ε 3,000); 1 
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-4-ethoxy-b-dxylofuranosyl]adenine (6b)
This compound was obtained as a foam in 90% yield: 
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-4-propoxy-b-dxylofuranosyl]adenine (6c)
This compound was obtained as a foam in 87% yield: 1 H NMR (CDCl 3 ) δ -0.12, 0.02, 0.11, 0.12 (12H, each as s, SiMe), 0.83 and 0.93 (18H, each as s, Si-t-Bu), 0.98 (3H, t, J vic =7. 4 Hz, 4′-OCH 2 CH 2 CH 3 ), 1.62 (2H, tt, J vic =7.6 and 6.9 Hz, 4′-OCH 2 CH 2 CH 3 ), 3.55 and 3.60 (2H, each as dt, J vic =6.9 and J gem =8. 8 Hz, 4′-OCH 2 ), 3.87, 3.96 (2H, each as d, J gem =11.0 Hz, H-5′), 4.15 (1H, dd, J 2′,3′ =2.5 Hz, J 3′,3′-OH =9. 3 Hz, H-3′), 4.60 (1H, dd, J 1′,2′ =3.9 Hz, J 2′,3′ =2. 5 Hz, H-2′), 5.55 (1H, d, J 3′,3′-OH =9. 3 Hz, 3′-OH), 5.89 (1H, d, J 1′,2′ =3. 9 Hz, H-1′), 6.08 (2H, brs, NH 2 ), 8 
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-4-isopropoxy-b-dxylofuranosyl]adenine (6d)
This compound was obtained as a foam in 80% yield: 1 H NMR (CDCl 3 ) δ -0.15, 0.02, 0.11, and 0.13 (12H, each as s, SiMe), 0.83 and 0.94 (18H, each as s, Si-t-Bu), 1.21 and 1.24 (6H, each as d, J vic =6.1 Hz, 4′-OCHMe 2 ), 3.87 and 3.93 (2H, each as d, J gem =10. 8 Hz, H-5′), 4.12 (1H, dd, J 2′,3′ =3.2 and J 3′,3′-OH =5. 8 
This compound was obtained as a foam in 60% overall yield from 3: 1 
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-4-octyloxy-b-dxylofuranosyl]adenine (6i)
This compound was obtained as a foam in 68% overall yield from 3: 1 
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-4-decyloxy-b-dxylofuranosyl]adenine (6j)
This compound was obtained as a foam in 66% overall yield from 1j: 1 
Preparation of 9-(2,3,5-tri-O-acetyl-4-methoxy-b-dxylofuranosyl)adenine (7a) from 6a as a typical procedure
A mixture of 6a (1.48 g, 2.81 mmol) and Bu 4 NF (1M THF solution, 7.03 ml, 7.03 mmol) in THF (15 ml) was stirred at room temperature for 3 h. The solvent was evaporated. The residue was dissolved in CH 3 CN (15 ml), and reacted with Ac 2 O (2.6 ml, 28.1 mmol) in the presence of Et 3 N (3.9 ml, 28.1 mmol) and 4-dimethylaminopyridine (686 mg, 5.62 mmol) at room temperature for 3 h. Evaporation of the solvent followed by column chromatography (CH 2 Cl 2 /MeOH=30/1) of the residue gave 7a (993.7 mg, 84%, foam): UV (MeOH): λ max 259 nm (ε 14,000), λ min 226 nm (ε 1,800); 1 
9-(2,3,5-Tri-O-acetyl-4-ethoxy-b-d-xylofuranosyl) adenine (7b)
This compound was obtained as a foam in quantitative yield: 1 
9-(2,3,5-Tri-O-acetyl-4-propoxy-b-d-xylofuranosyl) adenine (7c)
This compound was obtained as a foam in 98% yield: 1 
9-(2,3,5-Tri-O-acetyl-4-butoxy-b-d-xylofuranosyl) adenine (7e)
This compound was obtained as a foam in 91% yield: 1 
9-(2,3,5-Tri-O-acetyl-4-isobutoxy-b-d-xylofuranosyl) adenine (7f)
This compound was obtained as a foam in 94% yield:
9-(2,3,5-Tri-O-acetyl-4-tert-butoxy-b-d-xylofuranosyl) adenine (7g)
This compound was obtained as a foam in 99% yield: 
9-(2,3,5-Tri-O-acetyl-4-neopentyloxy-b-d-xylofuranosyl) adenine (7h)
9-(2,3,5-Tri-O-acetyl-4-decyloxy-b-d-xylofuranosyl) adenine (7j)
This compound was obtained as a foam in 94% yield: 1 
9-(2,3,5-Tri-O-acetyl-4-dodecyloxy-b-d-xylofuranosyl) adenine (7k)
This compound was obtained as a foam in 97% yield: 1 
9-(4-Ethoxy-b-d-xylofuranosyl)adenine (8b)
This compound was obtained as a foam in 90% yield: 1 
9-(4-Propoxy-b-d-xylofuranosyl)adenine (8c)
This compound was obtained as a foam in 94% yield: 1 H NMR (DMSO-d 6 ) δ 0.90 (3H, t, J vic =7. 2 Hz, 4′-OCH 2 CH 2 CH 3 ), 1.52 (2H, tt, J vic =7.2 and 6.7 Hz, 4′-OCH 2 CH 2 CH 3 ), 3.50 (2H, t, J vic =6. 7 Hz, 4′-OCH 2 CH 2 CH 3 ), 3.53 (1H, dd, J vic =4.9 and J gem =11. 8 Hz, H-5′a), 3.65 (2H, dd, J vic =7.5 and J gem =11. 8 
Virology
Assays detecting antibodies to HIV, hepatitis C virus (HCV) and bovine viral diarrhoea virus (BVDV) for compounds 8a-l were carried out according to the published procedures: HIV in MT-4 cells [6] , HCV in OR6 cells [7] and BVDV in Madin-Darby bovine kidney cells [8] .
Antiviral activity of comounds 8a-l were also evaluated against the following viruses: herpes simplex virus type-1 (HSV-1) strain KOS, thymidine kinase-deficient (TK -) HSV-1 KOS strain resistant to ACV, HSV type-2 strains Lyons and G, varicella-zoster virus (VZV) strain Oka, VZV/TKstrain 07-1, human cytomegalovirus strains AD-169 and Davis, vaccinia virus Lederle strain, respiratory syncytial virus strain Long, vesicular stomatitis virus, Coxsackie B4, Parainfluenza 3, Reovirus-1, Sindbis, Punta Toro, influenza A virus (H1N1 and H3N2), influenza B virus and feline coronavirus. These assays were based on the inhibition of virus-induced cytopathicity or plaque formation (for VZV) in human embryonic lung fibroblasts, African green monkey cells, human epithelial cells, Crandell feline kidney cells or Madin-Darby canine kidney cells. Briefly, confluent cell cultures in microtitre 96-well plates were inoculated with 100 50% cell culture infectious doses (CCID 50 ) of virus (1 CCID 50 being the virus dose to infect 50% of the cell cultures) or with 20 plaque-forming units (PFU; for VZV). After 1-2 h adsorption period, residual virus was removed and the cell cultures were incubated in the presence of varying concentrations of the test compounds. Viral cytopathicity or plaque formation (VZV) was recorded as soon as it reached completion in the control virus-infected cell cultures that were not treated with the test compounds. Antiviral activity was expressed as the 50% effective concentration, that is, effective concentration required to reduce virus-induced cytopathogenicity or viral plaque formation (VZV) by 50%.
Results
Starting from adenosine, 9-(3-deoxy-b-d-glycero-pento-3-enofuranosyl)adenine (1) was prepared according to the published procedure: reaction of adenosine with 2-acetoxyisobutyryl bromide followed by treatment of the resulting mixture of 2′,3′-vicinal bromo acetates with DBN (1,5-diazabicyclo[4.3.0]non-5-ene) [9] . Compound 1 was silylated to give 2. The 6-amino group of 2 was protected with a pivaloyl group to give 3 for prevention of N-oxide formation, which was reported previously (Figure 1 ) [10] .
Introduction of a variety of alkoxy groups to the 4′-position was carried out through epoxidation of 3 with m-CPBA in the presence of the respective alcohol as shown in Figure 2 . We have previously observed that, while epoxidation of 3 with dimethyldioxirane in acetone gave 4 stereoselectively, the reaction between 3 and m-CPBA in CH 2 Cl 2 produced several products, among which the 4′-(3-chlorobenzoyloxy) derivative was detected [10] . In the present case, the 4′-alkoxy derivatives (5) were obtained in high yield (compounds 5i-k were not obtained in pure form due to the contamination with a small amount of the respective alcohol, and were therefore isolated pure at the next stage). We could not observe any trace amount of product resulting from the attack of 3-chlorobenzoic acid to the 4′-position, presumably due to higher nucleophilicity of alcohols. The depicted stereochemistry of 5 was confirmed by NOE measurement, which is exemplified with 5a in Figure 3 . It is not clear if nucleophilic attack by alcohol takes place concurrently with the ring opening of the epoxide or an oxonium intermediate. However, we assume that attack of an alcohol from the α-face would be favoured even in the latter case due to the presence of the adenine base as well as the 3′-'up'-OH substituent, leading to the formation of the b-d-isomer (5).
Compound 5 was converted to 6 by reaction with NH 3 /MeOH. Desilylation of 6 was carried out in a conventional manner with Bu 4 NF in THF. For purification purpose, the resulting desilylated product was acetylated to give the 2′,3′,5′-tri-O-acetyl derivative 7.
As the last stage of the present synthesis, the acetate 7 was treated with Et 3 N in MeOH to yield a series of analytically pure 4′-alkoxy analogues (8a-l) of xylo-A.
Discussion
The compounds (8a-l) synthesized in the present study were evaluated for their inhibitory activity against a series of viruses: HSV-1 strain KOS, TK -HSV-1 KOS strain resistant to ACV, HSV-2 strains Lyons and G, VZV strain Oka, VZV/TKstrain 07-1, human cytomegalovirus strains AD-169 and Davis, vaccinia virus Lederle strain, respiratory syncytial virus strain Long, vesicular stomatitis virus, Coxsackie B4, Parainfluenza 3, Reovirus-1, Sindbis, Punta Toro, influenza A virus (H1N1 and H3N2), influenza B virus, feline coronavirus, HIV (in MT-4 cells), HCV (in OR6 cells), and BVDV (in Madin-Darby bovine kidney cells). However, these compounds did not show any significant antiviral activity. The assay detecting antibodies to BVDV highlighted that compounds with a longer 4′-alkoxy group (8i-k) become cytotoxic to the host cells ( Table 1) .
We assume that inactivity of the present compounds would be attributable to their different sugar conformation from that of xylo-A; therefore, enzymatic 5′-Ophosphorylation of these compounds might not function efficiently. In fact, when 1 H NMR spectra of 8a-l measured in DMSO-d 6 were compared with that of the reported xylo-A [11] , there was a considerable difference in the J value between H-1′ and H-2′: for 8a-l, J 1′,2′ =6.3∼7.1 Hz and for xylo-A, J 1′,2′ =2.0 Hz.
It might therefore be expected that the 5′-Ophosphorylated prodrugs of 8, such as the cycloSAL derivative [12] , could inhibit proliferation of certain viruses, which is the subject of future study. 
